Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin-GA3
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A **prodrug of daunorubicin** designed for selective activation in tumor tissues. DNR-GA3 is specifically synthesized for activation by human beta-glucuronidase, which is released in necrotic areas of tumor lesions, converting the prodrug into the active parent daunorubicin. In preclinical studies, DNR-GA3 shows substantially reduced toxicity compared to daunorubicin and demonstrates improved antitumor efficacy, especially in tumors with necrotic regions. The prodrug offers expanded maximum tolerated doses and rapid clearance compared to the parent drug.
- Other names
- N-[4-(daunorubicin-N-carbonyl-oxymethyl)phenyl] O-beta-glucuronyl carbamate
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin-GA3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin-GA3.